发明名称 PREDICTING RESPONSE TO CHEMOTHERAPY USING GENE EXPRESSION MARKERS
摘要 <p>The present invention provides gene expression information useful for predicting whether a cancer patient is likely to have a beneficial response to treatment with chemotherapy, comprising measuring, in a biological sample comprising a breast tumor sample obtained from the patient, the expression levels of gene subsets to obtain a risk score associated with a likelihood of a beneficial response to chemotherapy, wherein the score comprises at least one of the following variables: (i) Recurrence Score, (ii) ESRI Group Score; (iii) Invasion Group Score; (iv) Proliferation Group Score; and (v) the expression level of the RNA transcript of at least one of MYBL2 and SCUBE2, or the corresponding expression product. The invention further comprises a molecular assay-based algorithm to calculate the likelihood that the patient will have a beneficial response to chemotherapy based on the risk score.</p>
申请公布号 EP1836629(A1) 申请公布日期 2007.09.26
申请号 EP20050817266 申请日期 2005.11.04
申请人 GENOMIC HEALTH, INC.;NSABP FOUNDATION, INC. 发明人 BAKER, JOFFRE, B.;BRYANT, JOHN, L.;PAIK, SOONMYUNG;SHAK, STEVEN
分类号 C12Q1/68;G06F19/18;G06F19/20 主分类号 C12Q1/68
代理机构 代理人
主权项
地址